Research& Development

Learn more

INNOVATION, A PRIORITY

10%
10% of VIVACY’s revenue is invested in research every year.
10
10 years of engagement in research and innovations.
#1
Quality and product safety is our #1 priority
x11
x11 the production capacity in 8 years.
2
2 Patented Technologies: IPN-Like, Bi-SOFT®*.
6M
6 million treatments done in the world**.

INNOVATION, A PRIORITY

All Laboratoires VIVACY’s injectable products are designed and developed in the VIVACY Research & Development Laboratory in France, a site that has been entirely dedicated to innovation in the Anti-Ageing and Aesthetics fields.

Laboratoires VIVACY is always seeking to develop innovative, safe and high-quality injectable products that meet patient and doctor expectations and needs, while always remaining compliant with the European and International medical device regulations.

The R&D, Production, Quality & Regulatory Affairs teams collaborate to achieve a common goal: Providing high-end, well tolerated and safe injectable products for patients.

* IPN-Like Technology Patent delivered WO2009/071697 in 2008 and Bi-SOFT® Technology Patent submitted FR3064489 A1 in 2017.
** 7 millions of syringes sold in the world between 2008 and 31/08/18.